Verastem, Inc. (VSTM) company profile
Close on Nov 17, 2026Market cap $671.08MP/E –Yield –
About Verastem
Pharmaceutical Preparations, SIC 2834
Verastem is a biopharmaceutical company that develops and commercializes targeted cancer therapeutics directed at the RAS/MAPK signaling pathway. The company's primary commercial offering is AVMAPKI FAKZYNJA CO-PACK, an oral combination of avutometinib and defactinib. Its clinical development pipeline also features VS-7375, an oral inhibitor under evaluation for solid tumors such as pancreatic, non-small cell lung, and colorectal cancers. Verastem provides its therapies to adult patients diagnosed with recurrent low-grade serous ovarian cancer following prior systemic treatment, serving healthcare providers, academic medical institutions, and community oncology practices through specialized distributors and pharmacies.
Commercial sales are concentrated in the United States, where the business distributes treatments through specialty pharmacies and distributors. Clinical research operations involve patients and investigative sites across multiple international territories, including the United States, Australia, Canada, Europe, the United Kingdom, and Japan, alongside collaboration activities in China. The provided text does not disclose the location of the company's headquarters.
Summary of the business section of Verastem's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Verastem, Inc.
- Founded
- 2010
- Headquarters
- Needham, MA
- Address
- 117 Kendrick Street, Suite 500 02494
- Phone
- (781) 292-4200
- Website
- www.verastem.com
- Employees
- 102, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Massachusetts
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- VSTM
- Exchange
- Nasdaq
- IPO date
- Jan 27, 2012
- Shares outstanding
- 91M, Aug 3, 2026
- Public float
- $253.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Jun 1, 2023
- SEC CIK
- 1526119
- CUSIP
- 92337C203
- ISIN
- US92337C2035
- FIGI
- BBG001J2LSK5
- Share class FIGI
- BBG001V0G978
- LEI
- 549300IY0EFBIU8NQC81
- EIN
- 27-3269467
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dan Paterson | President and CEO, Director | 844,542 |
| Michael Kauffman | President of Development, Director | 8,666 |
| Daniel Calkins | Chief Financial Officer | 123,781 |
| Matthew Ros | Chief Operating Officer | 50,000 |
| Michael P. Bailey | Director | 108,000 |
| Michelle Robertson | Director | 52,666 |
| Paul A. Bunn | Director | 44,333 |
| Karin Anna Tollefson | Director | 52,666 |
| Eric K. Rowinsky | Director | 54,666 |
| John Johnson | Director | 52,666 |
| Brian M. Stuglik | Director | 137,147 |
| Anil Kapur | Director | 52,666 |
| Robert E. Gagnon | Director | 41,678 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.35M | $3.78M | $958.34K | $160 | – |
| FY2024 | $2.54M | $2.38M | $741.01K | $107 | – |
| FY2023 Mr.Brian Stuglik | $2.02M | $2.20M | $622.56K | $169 | – |
| FY2023 Mr.Daniel Paterson | $3.63M | $3.24M | $622.56K | $169 | – |
| FY2022 | $1.03M | -$1.33M | $487.59K | $20 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Daniel Paterson President and Chief Executive Officer | $674.00K | $1.16M | – | $489.32K | $24.99K | $2.35M | -7% |
| Matthew Ros Former Chief Operating Officer | $455.15K | $585.33K | – | $196.43K | $388.25K | $1.63M | – |
| Daniel Calkins Chief Financial Officer | $350.00K | $450.72K | – | $151.20K | $24.95K | $976.87K | +32% |
| Michael Kauffman President of Development | $30.00K | $62.33K | $75.66K | – | $105.00K | $272.99K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 27, 2012
- Offer price
- $10.00
- Securities offered
- 5,500,000
- Gross proceeds
- $55.00M
- Exchange
- Nasdaq
- First trading day
- Jan 27, 2012
- First-day close
- $11.09+10.9%
- Lock-up ends (est.)
- Jul 25, 2012
“Per share Total Public offering price $ 10.00 $ 55,000,000 Underwriting discounts and commissions $ 0.70 $ 3,850,000 Proceeds to Verastem, before expenses $ 9.30 $ 51,150,000 Certain of our existing stockholders and their affiliated entities have indicated an interest in purchasing an aggregate of up to approximate”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 102 full time equivalent employees, including a total of 23 employees with M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 9, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 30, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 2, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 27, 2012 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 23, 2012 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?